Dr. John Dillberger brings over 30 years of experience in toxicology, pathology, and drug development to our team. He has held senior leadership positions at Marion Merrell Dow, GlaxoWellcome, and Triangle Pharmaceuticals, and now, through J. Dillberger, LLC, a preclinical development consulting firm, specialises in safety evaluation for innovative therapeutics, medical devices, biologics, and combination products.
At GlaxoWellcome, Dr. Dillberger served as Head of US Pathology, Director of Safety Evaluation for US-Based Development Projects, and Worldwide Specialist in Oncology Drug Projects, where he advanced programs from discovery through late-stage development. At Triangle Pharmaceuticals, he directed toxicology efforts supporting clinical progression and regulatory approval strategies.
Dr. Dillberger has prepared safety evaluation packages for numerous clinical trial applications and marketing submissions in both the US and Europe. His firm has supported biotech clients and investors worldwide—including in North America, Europe, and Asia—helping advance cutting-edge therapeutics while de-risking investment decisions.
